Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2010

01.07.2010 | Hepatobiliary Tumors

Clinicopathological Prognostic Factors After Hepatectomy for Patients with Mass-Forming Type Intrahepatic Cholangiocarcinoma: Relevance of the Lymphatic Invasion Index

verfasst von: Ken Shirabe, MD, PhD, FACS, Yohei Mano, MD, Akinobu Taketomi, MD, Yuji Soejima, MD, Hideaki Uchiyama, MD, Shinichi Aishima, MD, Hiroto Kayashima, MD, Mizuki Ninomiya, MD, Yoshihiko Maehara, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The present study was conducted to clarify the pathological factors in patients who underwent surgery for mass-forming type intrahepatic cholangiocarcinoma (IHC).

Methods

From 1982 to July 2004, a total of 60 liver resections for mass-forming type IHC were performed at Kyushu University and its affiliated institutions. Portal venous, lymphatic, hepatic venous, and serosal invasion was examined by univariate and multivariate analyses for their prognostic value. The portal venous (PV) invasion index was defined as follows: PV0, portal venous invasion (−) and intrahepatic metastasis (−); PV1, portal venous invasion (+) or intrahepatic metastasis (+); PV2, portal venous invasion (+) and intrahepatic metastasis (+). The lymphatic invasion (LI) index was defined as follows: LI0, lymphatic duct invasion (−) and lymph node metastasis (−); LI1, intrahepatic lymphatic duct invasion (+) or lymph node metastasis (+); LI2, intrahepatic lymphatic duct invasion (+) and lymph node metastasis (+).

Results

In univariate analysis, statistically significant prognostic factors for poor outcome were tumor size (>5 cm), serosal invasion (+), PV1 or PV2, LI1 or LI2, histological grade (moderate and poor), hepatic venous invasion (+) and noncurative resection. After multivariate analysis, the lymphatic invasion index and histological grade were statistically independent prognostic factors for overall survival and recurrence-free survival.

Conclusions

In patients with mass-forming type IHC, lymphatic invasion is the most important invasion pathway, compared with serosal and portal and hepatic venous invasion. Stratification of the lymphatic invasion pathway by lymphatic invasion, including intrahepatic lymphatic duct invasion and lymph node metastasis, is a good predictor for prognosis in patients after hepatectomy for mass-forming type IHC.
Literatur
1.
Zurück zum Zitat Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277–87. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277–87.
2.
Zurück zum Zitat Uttravichien T, Bhudhisawadi V, Pairojkul C, et al. Intrahepatic cholangiocarcinoma in Thailand. J Hepatobiliary Pancreat Surg. 1999;6:128–35.CrossRef Uttravichien T, Bhudhisawadi V, Pairojkul C, et al. Intrahepatic cholangiocarcinoma in Thailand. J Hepatobiliary Pancreat Surg. 1999;6:128–35.CrossRef
3.
Zurück zum Zitat Yamamoto M, Takasaki K, Ohtsubo T, et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8:154–7.CrossRefPubMed Yamamoto M, Takasaki K, Ohtsubo T, et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8:154–7.CrossRefPubMed
4.
Zurück zum Zitat Jonas S, Thelen A, Benckert C, et al. (2009) Extended liver resection for intrahepatic cholangiocarcinoma. A comparison of the prognostic accuracy of the fifth and six editions of the TNM classification. Ann Surg. 249:303–9.CrossRefPubMed Jonas S, Thelen A, Benckert C, et al. (2009) Extended liver resection for intrahepatic cholangiocarcinoma. A comparison of the prognostic accuracy of the fifth and six editions of the TNM classification. Ann Surg. 249:303–9.CrossRefPubMed
5.
Zurück zum Zitat Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10:288–91.CrossRefPubMed Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10:288–91.CrossRefPubMed
6.
Zurück zum Zitat Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88:1463–6.CrossRefPubMed Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88:1463–6.CrossRefPubMed
7.
Zurück zum Zitat Choi SB, Kim KS, Choi JY, et al. The prognosis and surgical outcome of intrahepatic cholangiocarcinoma following surgical resection: Association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048–56.CrossRefPubMed Choi SB, Kim KS, Choi JY, et al. The prognosis and surgical outcome of intrahepatic cholangiocarcinoma following surgical resection: Association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048–56.CrossRefPubMed
8.
Zurück zum Zitat Nanashima A, Shibata K, Nakayama T, et al. Relationship between vessel count and postoperative survival in patients with intrahepatic cholangiocarcinoma. Am Surg Oncol. 2009;16:2123–9.CrossRef Nanashima A, Shibata K, Nakayama T, et al. Relationship between vessel count and postoperative survival in patients with intrahepatic cholangiocarcinoma. Am Surg Oncol. 2009;16:2123–9.CrossRef
9.
Zurück zum Zitat Yamashita Y, Taketomi A, Morita K, et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res. 2008;28:2353–60.PubMed Yamashita Y, Taketomi A, Morita K, et al. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res. 2008;28:2353–60.PubMed
10.
Zurück zum Zitat Sobin LH, Witterkind CH. TNM Classification of Malignant Tumours. 6th ed. Hoboken, NJ: John Wiley and Sons, 2002. Sobin LH, Witterkind CH. TNM Classification of Malignant Tumours. 6th ed. Hoboken, NJ: John Wiley and Sons, 2002.
11.
Zurück zum Zitat Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd ed. Tokyo, Japan: Kanehara, 2003. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd ed. Tokyo, Japan: Kanehara, 2003.
12.
Zurück zum Zitat Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. 2002;131:S159–64.CrossRefPubMed Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. 2002;131:S159–64.CrossRefPubMed
13.
Zurück zum Zitat Uenishi T, Yamazaki O, Yamamoto T, et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2005;12:479–83.CrossRefPubMed Uenishi T, Yamazaki O, Yamamoto T, et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2005;12:479–83.CrossRefPubMed
14.
Zurück zum Zitat Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127:498–505.CrossRefPubMed Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127:498–505.CrossRefPubMed
15.
Zurück zum Zitat Uenishi T, Yamazaki O, Horii K, Yamamoto T, Kubo S. A long-term survivor of intrahepatic cholangiocarcinoma with para-aortic lymph node metastasis. J Gastroenterol. 2006;41:391–2.CrossRefPubMed Uenishi T, Yamazaki O, Horii K, Yamamoto T, Kubo S. A long-term survivor of intrahepatic cholangiocarcinoma with para-aortic lymph node metastasis. J Gastroenterol. 2006;41:391–2.CrossRefPubMed
16.
Zurück zum Zitat Asakura H, Ohtsuka M, Ito H, et al. Long-term survivor after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology. 2005;52:722–4.PubMed Asakura H, Ohtsuka M, Ito H, et al. Long-term survivor after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology. 2005;52:722–4.PubMed
17.
Zurück zum Zitat Akatsu T, Shimazu M, Kawachi S, et al. Long-term survival of intrahepatic cholangiocarcinoma with hilar lymph node metastasis and portal vein involvement. Hepatogastroenterology. 2005;52:603–5.PubMed Akatsu T, Shimazu M, Kawachi S, et al. Long-term survival of intrahepatic cholangiocarcinoma with hilar lymph node metastasis and portal vein involvement. Hepatogastroenterology. 2005;52:603–5.PubMed
18.
Zurück zum Zitat Tamadl T, Kaczirek K, Gruenberger B, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg. 2009;96:919–25.CrossRef Tamadl T, Kaczirek K, Gruenberger B, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg. 2009;96:919–25.CrossRef
19.
Zurück zum Zitat Yamashita YI, Taketomi A, Fukuzawa K, et al. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cacners: a pilot study. Anticancer Res. 2006;26:771–6.PubMed Yamashita YI, Taketomi A, Fukuzawa K, et al. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cacners: a pilot study. Anticancer Res. 2006;26:771–6.PubMed
20.
Zurück zum Zitat Yamashita Y, Taketomi A, Itoh S, et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Jpn J Clin Oncol. 2010;40:24–8.CrossRefPubMed Yamashita Y, Taketomi A, Itoh S, et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Jpn J Clin Oncol. 2010;40:24–8.CrossRefPubMed
21.
Zurück zum Zitat Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008;26:3702–8.CrossRefPubMed Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008;26:3702–8.CrossRefPubMed
22.
Zurück zum Zitat Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study. The UK ABC-01 Study. Br J Cancer. 2009;101:621–7.CrossRefPubMed Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study. The UK ABC-01 Study. Br J Cancer. 2009;101:621–7.CrossRefPubMed
23.
Zurück zum Zitat Settakorn J, Kaewpila N, Burns GF, Leong AS. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol. 2005;58:1249–54.CrossRefPubMed Settakorn J, Kaewpila N, Burns GF, Leong AS. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol. 2005;58:1249–54.CrossRefPubMed
Metadaten
Titel
Clinicopathological Prognostic Factors After Hepatectomy for Patients with Mass-Forming Type Intrahepatic Cholangiocarcinoma: Relevance of the Lymphatic Invasion Index
verfasst von
Ken Shirabe, MD, PhD, FACS
Yohei Mano, MD
Akinobu Taketomi, MD
Yuji Soejima, MD
Hideaki Uchiyama, MD
Shinichi Aishima, MD
Hiroto Kayashima, MD
Mizuki Ninomiya, MD
Yoshihiko Maehara, MD, PhD, FACS
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0929-z

Weitere Artikel der Ausgabe 7/2010

Annals of Surgical Oncology 7/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.